Free tool
Largest one day declines
The 50 largest one day percentage moves lower recorded at the latest close. The largest moves were GENB at −20.8% and SYRE at −12.8%. By size, the list splits into 50 mid cap listings.
Switch view
All stocks50 of 23,178 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1D return | 1Y return |
|---|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | $2.07B | Mid cap | −20.80% | +27.59% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | −12.81% | +446.12% |
| HIMS | Hims & Hers Health, Inc. | $6.96B | Mid cap | −6.05% | −32.22% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | −5.40% | +445.10% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −4.79% | −8.02% |
| BFLY | Butterfly Network, Inc. | $2.30B | Mid cap | −4.42% | +450.32% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | −4.27% | +233.88% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −4.25% | −29.83% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −3.85% | −11.68% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | −3.57% | +136.66% |
| BHC | Bausch Health Companies Inc. | $2.43B | Mid cap | −3.27% | −10.45% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | −3.24% | +11.33% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −3.20% | −29.83% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | −3.09% | +144.07% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | −2.94% | +254.61% |
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −2.91% | −40.44% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | −2.74% | +10.65% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | −2.71% | +79.06% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | −2.71% | +366.53% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | −2.57% | +191.29% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | −2.56% | +615.10% |
| GRFS | Grifols, S.A. | $5.38B | Mid cap | −2.35% | −19.39% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | −2.34% | +555.07% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | −2.32% | +344.37% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | −2.16% | +188.94% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | −2.16% | +97.73% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | −2.12% | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | −2.08% | +181.38% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | −2.04% | +4.47% |
| WRBY | Warby Parker Inc. | $3.15B | Mid cap | −2.00% | −3.96% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | −1.97% | +135.93% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | −1.90% | +40.79% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | −1.90% | +133.47% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | −1.84% | +203.47% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | −1.81% | +209.53% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | −1.80% | +18.25% |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | −1.71% | +70.22% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | −1.59% | +93.71% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | −1.59% | +151.95% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | −1.58% | +79.51% |
| TMDX | TransMedics Group, Inc. | $3.19B | Mid cap | −1.47% | −21.43% |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | −1.45% | +41.83% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | −1.44% | +57.50% |
| ALMS | Alumis Inc. | $3.06B | Mid cap | −1.42% | +380.08% |
| STVN | Stevanato Group S.p.A. | $6.11B | Mid cap | −1.41% | −0.09% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | −1.31% | +9.35% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | −1.25% | +36.58% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | −1.20% | +356.93% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | −1.14% | +159.74% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | −1.12% | +22.19% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Micro and small cap listings are left out, so the list describes the market rather than thin trading, as are moves beyond 1,000% in a session, which are corporate actions the price series has not been restated for. This is a description of one day of price movement, nothing more. It says nothing about any company behind it.